In this week's EuroBiotech Report, FDA knocks Sanofi, Zealand off track, Gilead, Galapagos start Phase III program, Promethera plans IPO and more.

BioLineRx has teamed up with I-Bridge Capital to set up a Chinese drug development joint venture, iPharma.

In the same week that Medivation was bought out by Pfizer in a major $14 billion deal, its former vice president of clinical development Dr. Amy Peterson has…

The FDA has slapped a complete response letter onto Amgen for its experimental med to treat a hormonal imbalance in dialysis patients, dashing its hopes of a…

Promethera Biosciences is planning to IPO in April or May to raise €40 million for its pipeline of liver cell therapies.

Pfizer, $14 billion down after its biotech bonanza buyout of Medivation in cash this week, still has money in the pot to buy AstraZeneca’s antibiotics unit.

Clovis Oncology shares were up by about 30% in trading after market close--driven by expectations for its rucaparib to treat advanced ovarian cancer, which was…

A new deal from Novartis outlicenses its Phase II-ready, anti-PCSK9 antibody for a couple of inflammatory indications that include sepsis.